EMA Authorised: Beyfortus (nirsevimab) — Sanofi Winthrop Industrie

View source ↗

Summary

The European Medicines Agency authorised Beyfortus (nirsevimab) for prevention of respiratory syncytial virus infection in infants, with marketing authorization…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• BEYFORTUS (Nirsevimab)

Snippet

Status: Authorised. MAH: Sanofi Winthrop Industrie. Decision date: 12/03/2026